Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab vedotin vs physician's choice in CD30-positive cutaneous T-cell lymphoma
2010-024215-14Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals, Inc
- Start
- Apr 2012
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of brentuximab vedotin in cutaneous T-cell lymphoma (2 arms), sponsored by Millennium Pharmaceuticals, Inc. Primary endpoint: Objective response rate lasting at least 4 months. Started Apr 2012; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
cutaneous T-cell lymphoma
Beyond the preview
Go deeper on 2010-024215-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024215-14.